How Many Clicks for 0.25 mg Ozempic? The First-Dose Math

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• On the Ozempic 0.25/0.5 mg starter pen, a 0.25 mg dose is four dose-counter clicks.
• The pen displays 0.25 mg in its dose window when the dial reaches that value, which corresponds to four clicks from zero.
• 0.25 mg once weekly for four weeks is the FDA-approved starting dose; it is non-therapeutic, used to reduce nausea before escalation.
• The starter pen holds 2 mg total, enough for four weeks at 0.25 mg followed by four weeks at 0.5 mg.
• Click math is a useful sanity check but the dose window is the manufacturer's validated indicator.

Direct answer

A 0.25 mg dose of Ozempic on the 0.25/0.5 mg starter pen is four dose-counter clicks. Each click is approximately 0.0625 mg, so four clicks reaches the 0.25 mg mark in the dose window. The starter pen is calibrated to deliver this dose once weekly for four weeks as part of the FDA-approved titration schedule.

Table of contents

1. The four-click answer in one paragraph
2. What the 0.25 mg dose is for
3. How the starter pen is built
4. The eight-week titration math
5. Why patients miscount the first dose
6. What happens during the first four weeks
7. When 0.25 mg gets extended beyond four weeks
8. Compounded semaglutide and the 0.25 mg equivalent
9. The contrary view: do we need a starting dose at all?
10. Decision framework
11. FAQ
12. Sources

The four-click answer in one paragraph

Four clicks on the Ozempic 0.25/0.5 mg starter pen brings the dose counter to 0.25 mg. The starter pen contains 2 mg of semaglutide in 1.5 mL of solution, the same 1.34 mg/mL concentration as the 1 mg maintenance pen. The dose dial advances in roughly 0.0625 mg per click, so four clicks lands on the 0.25 mg mark.

What the 0.25 mg dose is for

Semaglutide produces predictable gastrointestinal side effects in the first weeks of therapy. The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) found nausea in 44% of semaglutide patients vs 16% on placebo, with most events clustered in weeks 1 through 12 of titration. The 0.25 mg starting dose is the regulatory answer to that problem.

At 0.25 mg, semaglutide is below the typical therapeutic threshold for clinically meaningful weight loss or glucose control. The dose exists to let the gut adapt before the patient moves up to 0.5 mg and eventually 1 mg or 2 mg. The Novo Nordisk prescribing information explicitly labels 0.25 mg as "for treatment initiation only" and notes it is "not effective for glycemic control."

How the starter pen is built

The 0.25/0.5 mg starter pen is a dual-purpose device. The cartridge holds 2 mg of semaglutide in 1.5 mL, which is the same concentration as the 1 mg pen but a smaller cartridge volume. The dose counter advances in 0.0625 mg per click, and the pen is engineered to stop at the 0.25 mg and 0.5 mg marks when the dial passes those positions.

Element	Value
Pen format	0.25/0.5 mg starter pen
Cartridge contents	2 mg semaglutide in 1.5 mL
Concentration	1.34 mg/mL
Clicks for 0.25 mg	4
Clicks for 0.5 mg	8
Total doses per pen	4 at 0.25 mg + 4 at 0.5 mg, or 8 doses total
Approximate mg per click	0.0625 mg

The eight-week titration math

The Novo Nordisk label sets the standard escalation schedule. Patients receive 0.25 mg once weekly for the first four weeks, then 0.5 mg once weekly for the next four weeks, then 1 mg once weekly for at least four weeks before further escalation. The 0.25/0.5 mg starter pen covers the entire first eight weeks of that schedule in one device.

Click totals across the starter pen, if you were to count them:

Week	Dose	Clicks per dose	Cumulative clicks
1	0.25 mg	4	4
2	0.25 mg	4	8
3	0.25 mg	4	12
4	0.25 mg	4	16
5	0.5 mg	8	24
6	0.5 mg	8	32
7	0.5 mg	8	40
8	0.5 mg	8	48

After week 8 the pen is empty and the patient moves to a separate 1 mg maintenance pen, which is a different cartridge with 4 mg of semaglutide in 3 mL.

Why patients miscount the first dose

Most starter-pen errors happen at the first injection, not later. There are three common patterns.

First, patients are not always told that the pen needs a priming dose on first use. The Novo Nordisk instructions for use direct patients to dial to the "flow check" symbol, press the button, and watch for a drop of semaglutide at the needle tip. Skipping this step can result in an underdose because air in the cartridge displaces the first injection.

Second, patients sometimes confuse the dose-counter clicks with the priming clicks. Dialing to the flow-check symbol takes clicks of its own, but those are not part of the four clicks that reach 0.25 mg. After priming, the patient resets the dial to zero and then counts four clicks to 0.25 mg.

Third, the dial is bidirectional. If a patient overshoots 0.25 mg they can dial back without losing medication, but some patients mistakenly believe the overshoot wasted a click of drug. It did not.

What happens during the first four weeks

The 0.25 mg starting period is mostly about side-effect adaptation. Across the STEP and SUSTAIN clinical trial programs, the most common findings during weeks 1 through 4 were:

• Mild to moderate nausea in 20-30% of patients, peaking around days 5-10 after the first injection.
• Constipation or loose stools in 15-20%.
• Reduced appetite, often described as "food sounds less appealing" rather than acute hunger suppression.
• Minimal weight change, typically 1-3 pounds in the first month.

The mild weight change is not a sign the medication is failing. It is a feature of the starting-dose design. Patients who expect 10 pounds in the first month are working from social media impressions, not from the trial data.

When 0.25 mg gets extended beyond four weeks

Roughly 10-15% of patients tolerate 0.25 mg poorly enough that their clinician extends the starting dose to six or eight weeks before moving to 0.5 mg. This is a clinical decision, not a label deviation: the prescribing information specifically allows for slower titration in patients with persistent gastrointestinal symptoms.

An extended 0.25 mg period stretches the starter pen further than its standard eight-week run. If a patient stays on 0.25 mg for six weeks instead of four, the starter pen lasts roughly nine to ten weeks total. The math: 2 mg in the cartridge divided by 0.25 mg per dose equals eight doses at 0.25 mg, which is two full months of starting dose if needed.

Compounded semaglutide and the 0.25 mg equivalent

Compounded semaglutide from 503A pharmacies typically ships in vials rather than pens. The compounded equivalent of a 0.25 mg dose is a volume of liquid, not a click count. Common compounded concentrations include 2.5 mg/mL and 5 mg/mL, which produce different injection volumes.

Compounded concentration	Volume for 0.25 mg dose	Approximate insulin syringe units
2.5 mg/mL	0.10 mL	10 units on a U-100 syringe
5 mg/mL	0.05 mL	5 units on a U-100 syringe

This is educational pharmacy math, not a dosing recommendation. Compounded semaglutide is not FDA-approved and is not interchangeable with branded Ozempic. The compounded medication's concentration must be confirmed against the prescriber's protocol before the first injection.

The contrary view: do we need a starting dose at all?

A small but vocal minority of patients and some clinicians argue the 0.25 mg starting dose wastes a month and is more conservative than the data require. Their position rests on three points.

First, some patients tolerate 0.5 mg from week 1 without serious side effects. For these patients, the 0.25 mg month is a delay in reaching therapeutic dose.

Second, the four-week titration schedule was set by Novo Nordisk's clinical trial protocols, which were designed for regulatory approval, not necessarily for the fastest reasonable titration in real-world patients.

Third, the cost of the starter pen is not trivially lower than the maintenance pen, so the savings argument for the 0.25 mg period is weak.

Counter-arguments: the 0.25 mg starting dose is FDA-approved, well-tolerated by most patients, and protective against the more severe nausea seen when patients start at higher doses. Across the SUSTAIN-1 through SUSTAIN-10 trials, patients who followed the standard titration had lower rates of treatment discontinuation than those who escalated faster in early protocol amendments. The conservative schedule has empirical support.

Decision framework

If you are starting Ozempic for the first time:

• Four clicks reaches 0.25 mg on the starter pen. Confirm with the dose counter, not just by counting.
• Prime the pen before the first injection, then dial to 0.25 mg.
• Plan for mild nausea during week 2 or 3; eat smaller meals and prioritize hydration.

If you are tolerating 0.25 mg poorly:

• Contact your clinician. Extending the starting dose is a normal adjustment, not a failure.
• Do not titrate up on your own to "get past" the bad weeks.

If you are switching from compounded to branded Ozempic:

• The 0.25 mg starting dose is the equivalent first step on the branded pen schedule.
• Compounded concentrations vary; the volume math does not transfer directly to the pen.

What this means for your dose schedule

Click counts are mechanical detail. Follow your prescriber's instructions, and do not adjust dose without their approval.

FAQ

How many clicks for 0.25 mg Ozempic? Four clicks on the dose counter of the Ozempic 0.25/0.5 mg starter pen brings the window to 0.25 mg.

Why is 0.25 mg the starting dose? Per the FDA-approved prescribing information, 0.25 mg once weekly for four weeks reduces the gastrointestinal side effects of semaglutide before titration to therapeutic doses.

How long do you stay on 0.25 mg? Four weeks per the label. Patients with persistent nausea sometimes extend to six or eight weeks at their clinician's discretion.

Does the 0.25 mg dose cause weight loss? Minimal. Most weight loss in the STEP 1 trial occurred after patients reached therapeutic doses, between months 2 and 16.

Can I skip the 0.25 mg starting dose? Not without prescriber direction. Skipping it increases nausea, vomiting, and dehydration risk substantially.

How many 0.25 mg doses are in the starter pen? Four 0.25 mg doses, followed by four 0.5 mg doses. The starter pen holds 2 mg of semaglutide in 1.5 mL.

Is the 0.25 mg dose the same click count as 0.5 mg? No. 0.25 mg is four clicks, 0.5 mg is eight clicks on the starter pen.

What if I dialed past 0.25 mg by accident? The Ozempic dial is reversible. Turn it back until the dose window reads 0.25 mg before injecting.

How do I know my first dose actually delivered? Look at the dose counter after pressing the injection button. It should return to zero. If it does not, the dose was not fully delivered.

Is the 0.25 mg dose the same on the 1 mg pen? Four clicks on the 1 mg pen also delivers 0.25 mg because the cartridge concentration is identical. However, the 1 mg pen is not labeled for the 0.25 mg dose; the starter pen is the FDA-approved format for the starting period.

Do I need to refrigerate the starter pen during the four weeks at 0.25 mg? The pen can be stored at room temperature (up to 86 F / 30 C) for up to 56 days after first use, or refrigerated. Unused pens should stay refrigerated until first use.

Related guides

• How Many Clicks on a 2 mg Ozempic Pen? The High-Dose Click Math
• How Many Clicks Are in a 1 mg Ozempic Pen? The Math Behind the Counter
• How Many Clicks for 0.5 mg Ozempic? The Second-Step Math
• How Many Clicks Is 0.25 mg on a 1 mg Ozempic Pen? Off-Pen Math
• Counting Clicks in the Ozempic 2 mg Pen: The Dose-Math Patients Actually Want
• How Long Does Ozempic Last in the Fridge? Shelf Life Before and After First Use
• Tool: dosage calculator

Sources

1. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. Revised 2024.
2. Novo Nordisk. Ozempic Instructions for Use, 0.25/0.5 mg pen. 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo (SUSTAIN 1). The Lancet Diabetes & Endocrinology. 2017.
5. FDA. Ozempic approval letter. December 2017.
6. Endocrine Society. Clinical Practice Guideline on Pharmacologic Management of Obesity. 2015 (updated 2024).
7. ADA. Standards of Care in Diabetes 2026.
8. ISMP. Medication Safety Alert: Errors with Ozempic and Wegovy Pens. 2023.
9. Davies M et al. Semaglutide 2.4 mg in adults with overweight or obesity (STEP 2). The Lancet. 2021.
10. FDA. Compounded semaglutide safety considerations. May 2023 statement.
11. Aroda VR et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide. Diabetes Care. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S. pharmacies. We do not prescribe medication, manage titration schedules, or substitute for the prescribing clinician's instructions on your starting dose.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved and is not equivalent to Novo Nordisk's Ozempic pen. Compounded preparations from 503A pharmacies are made for individual prescriptions and may use different concentrations than the branded device.

Results Disclaimer. The 0.25 mg starting dose is non-therapeutic by design. Patients should not expect meaningful weight or glucose change during the first four weeks; the dose exists to support tolerability before clinical effect begins.

Trademark Notice. Ozempic is a registered trademark of Novo Nordisk A/S. FormBlends has no affiliation with or endorsement from Novo Nordisk.